Two Brain-Derived Ethanolamides Inhibited Isolated Mouse Tissue and Shared THC Cross-Tolerance

Two endogenous fatty-acid ethanolamides inhibited electrically evoked contractions in isolated mouse vas deferens. Tissue obtained after THC pretreatment was less responsive. The experiment added functional evidence beyond receptor binding alone.

Binding and a functional response are different observations

The study examined ethanolamides designated anandamide 20:3 and 22:4, which had previously been identified in porcine brain and shown to bind cannabinoid sites. In isolated mouse tissue, both reduced an electrically evoked twitch response. Demonstrating a response in tissue strengthens an agonist hypothesis, although it does not establish every physiological role of the molecules.

THC pretreatment changed later tissue sensitivity

Vasa deferentia from THC-pretreated mice showed tolerance to the inhibitory effects of both compounds. The pretreatment was known to induce cannabinoid tolerance. This cross-tolerance supports a functional relationship, but does not by itself prove that the compounds have identical receptor affinity, metabolism or whole-animal effects.

The preparation limits the clinical inference

The measured endpoint was contraction of isolated reproductive-tract tissue, not fertility, sexual behavior or subjective intoxication. Identifying compounds in pig brain and testing their actions in mouse tissue also involves different biological contexts. Neither observation quantifies their normal contribution to human signaling.

Interpreting the evidence

This study helps distinguish chemical presence, receptor binding and functional activity. Its isolated-tissue findings should not be converted into a human reproductive diagnosis or a prediction of cannabis impairment.

Related reading: endogenous ligands administered as experimental drugs.

Research reference

Pertwee R; Griffin G; Hanus L; et al. (1994). Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia. European journal of pharmacology. doi:10.1016/0014-2999(94)90499-5. Evidence basis: study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

An Endogenous Pain Pathway Worked Independently of Endocannabinoid Mechanisms in Rodents

A rodent study found pain-related benefits from activating an endogenous adenosine pathway independently of opioid and endocannabinoid mechanisms. Endogenous pain modulation is therefore not automatically evidence of cannabinoid-receptor involvement. The intervention targeted adenosine signaling Researchers increased endogenous adenosine through kinase inhibition and separately tested a selective A3-receptor agonist. Receptor blockade…

Spread the love

Read Article: An Endogenous Pain Pathway Worked Independently of Endocannabinoid Mechanisms in Rodents

Cannabis in a Mixed-Drug Fatality Series: Hair and Blood Answer Different Exposure Questions

A Danish methadone-fatality study reported extensive mixed-drug exposure, including cannabis, and used segmental hair analysis to extend the exposure history beyond blood testing. That additional history was not proof of simultaneous intoxication from every listed substance. The two matrices supplied different information The study examined fatalities with both blood and…

Spread the love

Read Article: Cannabis in a Mixed-Drug Fatality Series: Hair and Blood Answer Different Exposure Questions

A Refractory Cancer-Pain Review’s Cannabinoid Option Was Not an Evidence-Based Ranking of Add-On Treatments

A 2015 review included cannabinoids among options for refractory cancer pain while describing weak benefit evidence across the reviewed drug strategies. Inclusion on a treatment-options list did not establish superiority or a favorable outcome for every patient. Refractory pain was a specific clinical question The review concerned pain not adequately…

Spread the love

Read Article: A Refractory Cancer-Pain Review’s Cannabinoid Option Was Not an Evidence-Based Ranking of Add-On Treatments

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us